Impact of COVID-19 pandemic on breast cancer neoadjuvant therapy: a retrospective institutional analysis
Annals of Oncology
; 33(Suppl. 3):S173-S173, 2022.
Article
in English
| GIM | ID: covidwho-2035751
ABSTRACT
Background:
COVID-19 pandemic motivated a reorganization of healthcare institutions, which may have led to a negative impact on cancer patients' treatment. This study compared the pathological response (PR) rate to neoadjuvant chemotherapy (NACT) in breast cancer (BC) patients who underwent treatment before (BCv) and during (DCv) the COVID-19 pandemic at our institution.
human diseases; coronavirus disease 2019; viral diseases; pandemics; public health; breast; breast cancer; neoplasms; adjuvants; medical treatment; retrospective studies; health care; health services; medical services; drug therapy; patients; trends; adverse effects; neutropenia; thromboembolism; disease course; statistical analysis; epidemiology; women; drug toxicity; symptoms; polymerase chain reaction; surveillance; monitoring; man; Severe acute respiratory syndrome coronavirus 2; Portugal; Homo; Hominidae; primates; mammals; vertebrates; Chordata; animals; eukaryotes; Severe acute respiratory syndrome-related coronavirus; Betacoronavirus; Coronavirinae; Coronaviridae; Nidovirales; positive-sense ssRNA Viruses; ssRNA Viruses; RNA Viruses; viruses; Community of Portuguese Language Countries; European Union Countries; high income countries; Mediterranean Region; OECD Countries; Southern Europe; Europe; very high Human Development Index countries; SARS-CoV-2; viral infections; breasts; mammary tumour; cancers; chemotherapy; adverse reactions; disease progression; statistical methods; Pcr
Full text:
Available
Collection:
Databases of international organizations
Database:
GIM
Type of study:
Experimental Studies
/
Observational study
Language:
English
Journal:
Annals of Oncology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS